Abstract

Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, and new therapeutic strategies are still required. Here we screened a synthetic cannabinoid library to identify compounds that uniformly reduce the viability of seven CRC cell lines. Material and Methods: Seven distinct CRC cell lines were treated with 10 μM cannabinoid compounds (from a library of 370 molecules) for 48 h, and cell viability was subsequently measured with MTS assay. Dose-response curves were conducted for compounds that were found to reproducibly reduce cell viability of one or more cell lines. Results: We identified 10 compounds from the library that were able to reduce cell viability of CRC cell lines (with an IC 50 ≤ 30 μM). Of these compounds, seven were specific for CRC cells, and six were effective in all CRC cell lines tested. Treatment with traditional phytocannabinoids (THC or CBD) was either ineffective or much less potent and only partially efficacious. Treatment with antagonists for the known cannabinoid receptors (alone or in combination) failed to block the activity of the most potent of identified compounds. Conclusion: We identified three families of cannabinoid compounds that reduce CRC cell viability through a noncanonical receptor mechanism. Future modification of these compounds may lead to the development of novel therapies to treat this disease.

Original languageEnglish (US)
Pages (from-to)272-281
Number of pages10
JournalCannabis and Cannabinoid Research
Volume3
Issue number1
DOIs
StatePublished - Mar 1 2018

Fingerprint

Cannabinoids
Colorectal Neoplasms
Cell Survival
Cell Line
Libraries
Cannabinoid Receptor Antagonists
Dronabinol
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Raup-Konsavage, Wesley M. ; Johnson, Megan ; Legare, Christopher A. ; Yochum, Gregory ; Morgan, Daniel ; Vrana, Kent. / Synthetic cannabinoid activity against colorectal cancer cells. In: Cannabis and Cannabinoid Research. 2018 ; Vol. 3, No. 1. pp. 272-281.
@article{1a50222383104d5dbefcee52e6f13438,
title = "Synthetic cannabinoid activity against colorectal cancer cells",
abstract = "Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, and new therapeutic strategies are still required. Here we screened a synthetic cannabinoid library to identify compounds that uniformly reduce the viability of seven CRC cell lines. Material and Methods: Seven distinct CRC cell lines were treated with 10 μM cannabinoid compounds (from a library of 370 molecules) for 48 h, and cell viability was subsequently measured with MTS assay. Dose-response curves were conducted for compounds that were found to reproducibly reduce cell viability of one or more cell lines. Results: We identified 10 compounds from the library that were able to reduce cell viability of CRC cell lines (with an IC 50 ≤ 30 μM). Of these compounds, seven were specific for CRC cells, and six were effective in all CRC cell lines tested. Treatment with traditional phytocannabinoids (THC or CBD) was either ineffective or much less potent and only partially efficacious. Treatment with antagonists for the known cannabinoid receptors (alone or in combination) failed to block the activity of the most potent of identified compounds. Conclusion: We identified three families of cannabinoid compounds that reduce CRC cell viability through a noncanonical receptor mechanism. Future modification of these compounds may lead to the development of novel therapies to treat this disease.",
author = "Raup-Konsavage, {Wesley M.} and Megan Johnson and Legare, {Christopher A.} and Gregory Yochum and Daniel Morgan and Kent Vrana",
year = "2018",
month = "3",
day = "1",
doi = "10.1089/can.2018.0065",
language = "English (US)",
volume = "3",
pages = "272--281",
journal = "Cannabis and Cannabinoid Research",
issn = "2378-8763",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

Synthetic cannabinoid activity against colorectal cancer cells. / Raup-Konsavage, Wesley M.; Johnson, Megan; Legare, Christopher A.; Yochum, Gregory; Morgan, Daniel; Vrana, Kent.

In: Cannabis and Cannabinoid Research, Vol. 3, No. 1, 01.03.2018, p. 272-281.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synthetic cannabinoid activity against colorectal cancer cells

AU - Raup-Konsavage, Wesley M.

AU - Johnson, Megan

AU - Legare, Christopher A.

AU - Yochum, Gregory

AU - Morgan, Daniel

AU - Vrana, Kent

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, and new therapeutic strategies are still required. Here we screened a synthetic cannabinoid library to identify compounds that uniformly reduce the viability of seven CRC cell lines. Material and Methods: Seven distinct CRC cell lines were treated with 10 μM cannabinoid compounds (from a library of 370 molecules) for 48 h, and cell viability was subsequently measured with MTS assay. Dose-response curves were conducted for compounds that were found to reproducibly reduce cell viability of one or more cell lines. Results: We identified 10 compounds from the library that were able to reduce cell viability of CRC cell lines (with an IC 50 ≤ 30 μM). Of these compounds, seven were specific for CRC cells, and six were effective in all CRC cell lines tested. Treatment with traditional phytocannabinoids (THC or CBD) was either ineffective or much less potent and only partially efficacious. Treatment with antagonists for the known cannabinoid receptors (alone or in combination) failed to block the activity of the most potent of identified compounds. Conclusion: We identified three families of cannabinoid compounds that reduce CRC cell viability through a noncanonical receptor mechanism. Future modification of these compounds may lead to the development of novel therapies to treat this disease.

AB - Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, and new therapeutic strategies are still required. Here we screened a synthetic cannabinoid library to identify compounds that uniformly reduce the viability of seven CRC cell lines. Material and Methods: Seven distinct CRC cell lines were treated with 10 μM cannabinoid compounds (from a library of 370 molecules) for 48 h, and cell viability was subsequently measured with MTS assay. Dose-response curves were conducted for compounds that were found to reproducibly reduce cell viability of one or more cell lines. Results: We identified 10 compounds from the library that were able to reduce cell viability of CRC cell lines (with an IC 50 ≤ 30 μM). Of these compounds, seven were specific for CRC cells, and six were effective in all CRC cell lines tested. Treatment with traditional phytocannabinoids (THC or CBD) was either ineffective or much less potent and only partially efficacious. Treatment with antagonists for the known cannabinoid receptors (alone or in combination) failed to block the activity of the most potent of identified compounds. Conclusion: We identified three families of cannabinoid compounds that reduce CRC cell viability through a noncanonical receptor mechanism. Future modification of these compounds may lead to the development of novel therapies to treat this disease.

UR - http://www.scopus.com/inward/record.url?scp=85063185224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063185224&partnerID=8YFLogxK

U2 - 10.1089/can.2018.0065

DO - 10.1089/can.2018.0065

M3 - Article

VL - 3

SP - 272

EP - 281

JO - Cannabis and Cannabinoid Research

JF - Cannabis and Cannabinoid Research

SN - 2378-8763

IS - 1

ER -